# Gan and Lee Pharmaceuticals, USA clinical trials: 29 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 29 trials with Gan and Lee Pharmaceuticals, USA as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Gan and Lee Pharmaceuticals, USA: 29 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/gan-and-lee-pharmaceuticals-usa

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 29
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 29, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 21, 2025 | NCT07242664 | Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State | Gan and Lee Pharmaceuticals, USA | Phase 1 | Recruiting | Type 1 Diabetes Mellitis | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07242664) |
| August 28, 2025 | NCT07146347 | Comparison Study of Insulin GZR4 With Insulin Degludec | Gan and Lee Pharmaceuticals, USA | Phase 1 | Recruiting | Type 2 Diabetes | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07146347) |
| December 17, 2024 | NCT06737042 | Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants | Gan and Lee Pharmaceuticals, USA | Phase 2 | Completed | Obesity and Overweight | 326 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06737042) |
| November 1, 2024 | NCT06670209 | A Phase I Clinical Study to Evaluate the Effect of GZR18 Injection on the Pharmacokinetics of Oral Metformin Hydrochloride Tablets in... | Gan and Lee Pharmaceuticals, USA | Phase 1 | Unknown | Type 2 Diabetes | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06670209) |
| August 19, 2024 | NCT06558708 | A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD | Gan and Lee Pharmaceuticals, USA | Phase 2 | Unknown | Type 2 Diabetes | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06558708) |
| August 16, 2024 | NCT06556641 | A Clinical Study of GZR33 and GZR101 in Healthy Subjects | Gan and Lee Pharmaceuticals, USA | Phase 1 | Completed | Healthy Subjects | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06556641) |
| August 14, 2024 | NCT06554054 | A Study of GZR18 Tablet in Chinese Healthy Subjects | Gan and Lee Pharmaceuticals, USA | Phase 1 | Unknown | Diabetes Mellitus, Type 2 | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06554054) |
| August 14, 2024 | NCT06553248 | A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes | Gan and Lee Pharmaceuticals, USA | Phase 1 | Completed | Diabetes | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06553248) |
| August 12, 2024 | NCT06548997 | A Phase I Study of GZR18 Injection in Healthy Subjects | Gan and Lee Pharmaceuticals, USA | Phase 1 | Completed | Type 2 Diabetes, Overweight and Obesity | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06548997) |
| August 12, 2024 | NCT06548945 | A Phase I Study of GZR18 Injection in Obese/Overweight Subjects | Gan and Lee Pharmaceuticals, USA | Phase 1 | Completed | Overweight and Obesity | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06548945) |
| August 12, 2024 | NCT06548932 | A Study to Evaluate the Safety, Tolerance, PK and PD Parameters of GZR33 and GZR101 in Healthy Male Adult Subjects | Gan and Lee Pharmaceuticals, USA | Phase 1 | Completed | Healthy Subjects | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06548932) |
| August 12, 2024 | NCT06548906 | A Study of GZR4 Injection at Different Injection Sites | Gan and Lee Pharmaceuticals, USA | Phase 1 | Unknown | Healthy Subjects | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06548906) |
| August 12, 2024 | NCT06548815 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single-dose GZR4 | Gan and Lee Pharmaceuticals, USA | Phase 1 | Completed | Diabetes | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06548815) |
| August 9, 2024 | NCT06547502 | Pharmacokinetics and Safety Profile of a Single Dose GZR4 in Subjects with Renal Impairment | Gan and Lee Pharmaceuticals, USA | Phase 1 | Completed | Diabetes | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06547502) |
| February 13, 2024 | NCT06256562 | A Study of GZR18 Injection in Obese/Overweight Patients | Gan and Lee Pharmaceuticals, USA | Phase 2 | Completed | Obesity, Overweight | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06256562) |
| February 13, 2024 | NCT06256549 | A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus | Gan and Lee Pharmaceuticals, USA | Phase 2 | Unknown | Type 2 Diabetes | 272 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06256549) |
| February 13, 2024 | NCT06256536 | A Study of GZR18 Injection in Chinese Obese/Overweight Patients | Gan and Lee Pharmaceuticals, USA | Phase 1/2 | Completed | Obesity, Overweight | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06256536) |
| February 13, 2024 | NCT06256523 | A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM) | Gan and Lee Pharmaceuticals, USA | Phase 1/2 | Completed | Type 2 Diabetes | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06256523) |
| January 11, 2024 | NCT06202079 | A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus | Gan and Lee Pharmaceuticals, USA | Phase 2 | Completed | Diabetes Mellitus, Type 2 | 179 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06202079) |
| January 10, 2024 | NCT06199505 | A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM | Gan and Lee Pharmaceuticals, USA | Phase 2 | Completed | Type 2 Diabetes | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06199505) |
| April 14, 2022 | NCT05328726 | Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects | Gan and Lee Pharmaceuticals, USA | Phase 1 | Completed | Diabetes Mellitus, Type 2 | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05328726) |
| June 23, 2020 | NCT04444427 | Evaluation of GLR2007 for Advanced Solid Tumors | Gan and Lee Pharmaceuticals, USA | Phase 1/2 | Completed | Non-small Cell Lung Cancer, Glioblastoma Multiforme | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04444427) |
| February 5, 2020 | NCT04254380 | Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro | Gan and Lee Pharmaceuticals, USA | Phase 3 | Withdrawn | Diabetes Mellitus, Type 1 | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04254380) |
| January 23, 2020 | NCT04237129 | PK/PD Study of Gan & Lee Insulin Aspart Injection vs. US & EU NovoLog®/NovoRapid® in Healthy Males | Gan and Lee Pharmaceuticals, USA | Phase 1 | Completed | Diabetes Mellitus, Type 1 | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04237129) |
| January 22, 2020 | NCT04236895 | PK/PD Biosimilarity Study of Gan & Lee Insulin Glargine Injection vs.US & EU Lantus® in Type 1 Diabetes Mellitus Patients | Gan and Lee Pharmaceuticals, USA | Phase 1 | Completed | Diabetes Mellitus, Type 1 | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04236895) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 17 |
| Phase 1/2 | 3 |
| Phase 2 | 6 |
| Phase 3 | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 21 |
| Unknown | 5 |
| Recruiting | 2 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 11 |
| Diabetes Mellitus | 9 |
| Insulin Resistance | 6 |
| Overweight | 5 |
| Obesity | 5 |
| Diabetes Mellitus, Type 1 | 5 |
| Weight Loss | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Glioblastoma | 1 |
| Breast Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Security system companies in the United States](https://specstream.ai/data/businesses/security-system-companies/united-states)
- [Pubs in the United States](https://specstream.ai/data/businesses/pubs/united-states)
- [Plastic injection molders in the United States](https://specstream.ai/data/businesses/plastic-injection-molders/united-states)
- [Otolaryngology practices in the United States](https://specstream.ai/data/businesses/otolaryngology-practices/united-states)
- [Mexican restaurants in the United States](https://specstream.ai/data/businesses/mexican-restaurants/united-states)
